Gene therapy for wet AMD passes early safety check in small study
NCT ID NCT06817343
First seen Apr 29, 2026 · Last updated Apr 29, 2026
Summary
This study checks the long-term safety of a gene therapy called EXG102-031 for people with wet age-related macular degeneration (AMD), a condition that causes blurry or lost central vision. Twelve people who already received the gene therapy in an earlier study will be followed for up to 4 years to monitor side effects and see if their vision stays stable. The goal is to make sure the treatment is safe enough to test in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erie Retina Research
Erie, Pennsylvania, 16507, United States
-
Sierra Eye Associates
Reno, Nevada, 89502, United States
Conditions
Explore the condition pages connected to this study.